Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

References

• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–88. doi:10.1056/NEJM200105033441807. PMID:11333996.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position paper. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002;77(40):329–40.
   Google Scholar
• World Health Organization. 2015. Meningococcal meningitis. Fact sheet no 141. http://www.who.int/mediacentre/factsheets/fs141/en/; [accessed 6 June 2017].
   Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(Suppl 2):S3−S11. doi:10.1016/j.jadohealth.2016.04.012. PMID:27449148.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Greenwood B, Head C, Plotkin SA, Safadi MA, Saha S, Taha MK, Tomori O, Gessner BD. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334–46. doi:10.1016/S1473-3099(15)00217-0. PMID:26453240.
   PubMed Web of Science ®Google Scholar
• Borrow R, Lee J-S, Vázquez JA, Enwere G, Taha M-K, Kamiya H, Kim HM, Jo DS. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34(48):5855–62. doi:10.1016/j.vaccine.2016.10.022. PMID:27780631.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F. Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. J Adolesc Health. 2016;59(2 Suppl):S12−20. doi:10.1016/j.jadohealth.2016.03.041. PMID:27449145.
   PubMed Web of Science ®Google Scholar
• Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034–41. doi:10.1016/j.vaccine.2017.03.007. PMID:28314560.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active bacterial Core surveillance (ABCs) report, Emerging Infections Program Network, Neisseria meningitidis (2015). Available from www.cdc.gov/abcs/reports-findings/survreports/mening15.html; [accessed 2 October 2017].
   Google Scholar
• Safadi MA, O'Ryan M, Valenzuela Bravo MT, Brandileone MC, Gorla MC, de Lemos AP, Moreno G, Vazquez JA, Lopez EL, Taha MK, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33(48):6529–36. doi:10.1016/j.vaccine.2015.10.055. PMID:26597036.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control, R.O.C (Taiwan). Communicable Disease &Prevention. Meningococcal meningitis. 2017. Available from http://www.cdc.gov.tw/english/info.aspx?treeid=E79C7A9E1E9B1CDF&nowtreeid=E02C24F0DACDD729&tid=E3F090F82DB3B457; [accessed 22 September 2017].
   Google Scholar
• Toneatto D, Pizza M, Masignani V, Rino R. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev of Vacc. 2017;16(5):433–51. doi:10.1080/14760584.2017.1308828.
   PubMed Web of Science ®Google Scholar
• O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi:10.1007/s40265-013-0155-7. PMID:24338083.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3. PMID:28100432.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bexsero. Meningococcal group B Vaccine (rDNA, component, adsorbed). Procedure No. EMEA/H/C/002333. 2012. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002333/WC500137883.pdf; [accessed 10 April 2017].
   Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82. doi:10.1001/jama.2012.85. PMID:22318278.
   PubMed Web of Science ®Google Scholar
• Safadi MAP, Martinon-Torres F, Weckx LY, Moreira Junior ED, da Fonseca Lima EJ, Mensi I, Calabresi M, Toneatto D. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial. Vaccine. 2017;35(16):2052–9. doi:10.1016/j.vaccine.2017.03.002. PMID:28318767.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. doi:10.1016/S0140-6736(12)61961-8. PMID:23324563.
   PubMed Web of Science ®Google Scholar
• Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, et al. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. Pediatr Infect Dis J. 2016;35(4):e113−23. doi:10.1097/INF.0000000000001056. PMID:26756390.
   PubMed Web of Science ®Google Scholar
• Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017;35(2):395–402. doi:10.1016/j.vaccine.2016.11.009. PMID:27914744.
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. doi:10.4161/hv.28666. PMID:25424809.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Choe YJ, Hong YJ, Kim KH, Park SE, Kim YK, Oh CE, Lee H, Song H, Bock H, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea–A randomised trial. Vaccine. 2016;34(9):1180–6. doi:10.1016/j.vaccine.2016.01.033. PMID:26826544.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–26. doi:10.1084/jem.129.6.1307. PMID:4977280.
   PubMed Web of Science ®Google Scholar
• Clopper C. J., Pearson E. S. The use of confidence limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13. doi:10.1093/biomet/26.4.404.
   Google Scholar